Thomas P. Huecksteadt
University of Utah
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Thomas P. Huecksteadt.
American Journal of Physiology-cell Physiology | 2002
Sukhdev S. Brar; Thomas P. Kennedy; Anne Sturrock; Thomas P. Huecksteadt; Mark T. Quinn; A. Richard Whorton; John R. Hoidal
Malignant melanoma cells spontaneously generate reactive oxygen species (ROS) that promote constitutive activation of the transcription factor nuclear factor-kappaB (NF-kappaB). Although antioxidants and inhibitors of NAD(P)H oxidases significantly reduce constitutive NF-kappaB activation and suppress cell proliferation (11), the nature of the enzyme responsible for ROS production in melanoma cells has not been determined. To address this issue, we now have characterized the source of ROS production in melanoma cells. We report that ROS are generated by isolated, cytosol-free melanoma plasma membranes, with inhibition by NAD(P)H oxidase inhibitors. The p22(phox), gp91(phox), and p67(phox) components of the human phagocyte NAD(P)H oxidase and the gp91(phox) homolog NOX4 were demonstrated in melanomas by RT-PCR and sequencing, and protein product for both p22(phox) and gp91(phox) was detected in cell membranes by immunoassay. Normal human epidermal melanocytes expressed only p22(phox) and NOX4. Melanoma proliferation was reduced by NAD(P)H oxidase inhibitors and by transfection of antisense but not sense oligonucleotides for p22(phox) and NOX4. Also, the flavoprotein inhibitor diphenylene iodonium inhibited constitutive DNA binding of nuclear protein to the NF-kappaB and cAMP-response element consensus oligonucleotides, without affecting DNA binding activity to activator protein-1 or OCT-1. This suggests that ROS generated in autocrine fashion by an NAD(P)H oxidase may play a role in signaling malignant melanoma growth.
American Journal of Physiology-lung Cellular and Molecular Physiology | 2009
Saleh Ismail; Anne Sturrock; Ping Wu; Barbara C. Cahill; Kimberly Norman; Thomas P. Huecksteadt; Karl Sanders; Thomas P. Kennedy; John R. Hoidal
Persistent hypoxia can cause pulmonary arterial hypertension that may be associated with significant remodeling of the pulmonary arteries, including smooth muscle cell proliferation and hypertrophy. We previously demonstrated that the NADPH oxidase homolog NOX4 mediates human pulmonary artery smooth muscle cell (HPASMC) proliferation by transforming growth factor-beta1 (TGF-beta1). We now show that hypoxia increases HPASMC proliferation in vitro, accompanied by increased reactive oxygen species generation and NOX4 gene expression, and is inhibited by antioxidants, the flavoenzyme inhibitor diphenyleneiodonium (DPI), and NOX4 gene silencing. HPASMC proliferation and NOX4 expression are also observed when media from hypoxic HPASMC are added to HPASMC grown in normoxic conditions, suggesting autocrine stimulation. TGF-beta1 and insulin-like growth factor binding protein-3 (IGFBP-3) are both increased in the media of hypoxic HPASMC, and increased IGFBP-3 gene expression is noted in hypoxic HPASMC. Treatment with anti-TGF-beta1 antibody attenuates NOX4 and IGFBP-3 gene expression, accumulation of IGFBP-3 protein in media, and proliferation. Inhibition of IGFBP-3 expression with small interfering RNA (siRNA) decreases NOX4 gene expression and hypoxic proliferation. Conversely, NOX4 silencing does not decrease hypoxic IGFBP-3 gene expression or secreted protein. Smad inhibition does not but the phosphatidylinositol 3-kinase (PI3K) signaling pathway inhibitor LY-294002 does inhibit NOX4 and IGFBP-3 gene expression, IGFBP-3 secretion, and cellular proliferation resulting from hypoxia. Immunoblots from hypoxic HPASMC reveal increased TGF-beta1-mediated phosphorylation of the serine/threonine kinase (Akt), consistent with hypoxia-induced activation of PI3K/Akt signaling pathways to promote proliferation. We conclude that hypoxic HPASMC produce TGF-beta1 that acts in an autocrine fashion to induce IGFBP-3 through PI3K/Akt. IGFBP-3 increases NOX4 gene expression, resulting in HPASMC proliferation. These observations add to our understanding hypoxic pulmonary vascular remodeling.
Journal of Clinical Investigation | 1992
Gregory P. Dupont; Thomas P. Huecksteadt; Bruce C. Marshall; Una S. Ryan; John R. Michael; John R. Hoidal
The central importance of xanthine dehydrogenase (XDH) and xanthine oxidase (XO) in the pathobiochemistry of a number of clinical disorders underscores the need for a comprehensive understanding of the regulation of their expression. This study was undertaken to examine the effects of cytokines on XDH/XO activity and gene expression in pulmonary endothelial cells. The results indicate that IFN-gamma is a potent inducer of XDH/XO activity in rat lung endothelial cells derived from both the microvasculature (LMVC) and the pulmonary artery. In contrast, interferon-alpha/beta, tumor necrosis factor-alpha, interleukin-1 or -6, lipopolysaccharide and phorbol myristate acetate have no demonstrable effect. The increase in XDH/XO activity requires new protein synthesis. By Northern analysis, IFN-gamma markedly increases the level of the 5.0-kb XDH/XO mRNA in LMVC. The increase is due, in part, to increased transcription rate of the XDH/XO gene. Transcriptional activation does not require new protein synthesis. The physiologic relevance of these observations was evaluated by administering IFN-gamma to rats. Intraperitoneal administration leads to an increased XDH/XO activity and XDH/XO mRNA level in rat lungs. In sum, IFN-gamma is a potent and biologically relevant inducer of XDH/XO expression; the major site of upregulation occurs at the transcriptional level.
American Journal of Physiology-lung Cellular and Molecular Physiology | 2006
Anne Sturrock; Barbara C. Cahill; Kimberly Norman; Thomas P. Huecksteadt; Kenneth E. Hill; Karl Sanders; Shreekanth V. Karwande; James C. Stringham; David A. Bull; Martin Gleich; Thomas P. Kennedy; John R. Hoidal
American Journal of Physiology-cell Physiology | 2003
Sukhdev S. Brar; Zachary Corbin; Thomas P. Kennedy; Richelle Hemendinger; Lisa R. Thornton; Bettina Bommarius; Rebecca S. Arnold; A. Richard Whorton; Anne Sturrock; Thomas P. Huecksteadt; Mark T. Quinn; Kevin Krenitsky; Kristia G. Ardie; J. David Lambeth; John R. Hoidal
American Journal of Physiology-lung Cellular and Molecular Physiology | 2007
Anne Sturrock; Thomas P. Huecksteadt; Kimberly Norman; Karl Sanders; Thomas M. Murphy; Pasquale Chitano; Kimberly Wilson; John R. Hoidal; Thomas P. Kennedy
Journal of Immunology | 1994
Kathleen D. Pfeffer; Thomas P. Huecksteadt; John R. Hoidal
American Journal of Physiology-lung Cellular and Molecular Physiology | 2002
Sukhdev S. Brar; Thomas P. Kennedy; Anne Sturrock; Thomas P. Huecksteadt; Mark T. Quinn; Thomas M. Murphy; Pasquale Chitano; John R. Hoidal
American Journal of Physiology-cell Physiology | 2001
Sukhdev S. Brar; Thomas P. Kennedy; A. Richard Whorton; Anne Sturrock; Thomas P. Huecksteadt; Andrew J. Ghio; John R. Hoidal
Genomics | 1996
Ping Xu; Thomas P. Huecksteadt; John R. Hoidal